Table of contents
In this issue
p189 | doi:10.1038/nrd1352
Editorial: The communication barrier: drug discovery's final frontier?
p191 | doi:10.1038/nrd1357
News and Analysis
News
Aventis-Sanofi: a good R&D merger?
p193 | doi:10.1038/nrd1358
News in Brief
News
Scientists slam rationale behind largest HIV vaccine trial
p195 | doi:10.1038/nrd1359
Patent watch
Double attack on patent for Wellbutrin sustained-release agent
p196 | doi:10.1038/nrd1336
Patent watch
Compensation for Japanese patent holders
p196 | doi:10.1038/nrd1337
Patent watch
Lack of descriptive support results in no interference-in-fact
p196 | doi:10.1038/nrd1339
From the analyst's couch
Betting on biogenerics
p197 | doi:10.1038/nrd1333
Fresh from the Pipeline
Omalizumab
p199 | doi:10.1038/nrd1334
Research Highlights
Anticancer drugs: Overcoming inhibition
p201 | doi:10.1038/nrd1354
Gpcrs: Family traits
p202 | doi:10.1038/nrd1335
Cardiovascular disease: Healing hearts
p202 | doi:10.1038/nrd1355
Target validation: Regulating the beat
p203 | doi:10.1038/nrd1338
RNA interference: Eight steps to silence
p204 | doi:10.1038/nrd1340
In brief
Antiviral drugs | Neurological disease | Anticancer drugs | Kinases
p204 | doi:10.1038/nrd1351
Reviews
Neurodegenerative diseases and oxidative stress
Kevin J. Barnham, Colin L. Masters & Ashley I. Bush
p205 | doi:10.1038/nrd1330
Article series: Case Histories
Case history
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Tom Matthews, Miklos Salgo, Michael Greenberg, Jain Chung, Ralph DeMasi & Dani Bolognesi
p215 | doi:10.1038/nrd1331
First dose of potential new medicines to humans: how animals help
Peter Greaves, Andrew Williams & Malcolm Eve
p226 | doi:10.1038/nrd1329
Twenty Questions
Editorial
Highlighting the pitfalls and possibilities of drug research
Clare Ellis & Adam Smith
p238 | doi:10.1038/nrd1332
The state of ion channel research in 2004
The Nature Reviews Drug Discovery Ion Channel Questionnaire Participants
p239 | doi:10.1038/nrd1361
